Biosimilar timeline

NOVOLIN 70/30 biosimilars — when can they launch?

NOVOLIN 70/30 (human insulin) · BLA019991 · NOVO NORDISK INC

Reference exclusivity
2003-06-25
expired
Original approval
1991-06-25
FDA BLA019991
Originator
NOVO NORDISK INC
Marketed by Novo Nordisk A/S

Where NOVOLIN 70/30 sits in the biosimilar timeline

BPCIA reference product exclusivity for NOVOLIN 70/30 expired in 2003. Biosimilars are eligible for FDA 351(k) approval in the US. Active biosimilar applications and approvals will appear here as they're filed.

Under the US Biologics Price Competition and Innovation Act (BPCIA), a reference biologic is protected from biosimilar competition for 12 years from FDA approval (with 4 years of data exclusivity preventing 351(k) submissions). Biosimilars enter via the abbreviated 351(k) pathway, which requires comparability — not exact identity — to the reference product.

Key dates for NOVOLIN 70/30

EventDateStatus
FDA approval (BLA filed by NOVO NORDISK INC) 1991-06-25 Past
4-year data exclusivity ends (first biosimilar 351(k) submission permitted) 1995-06-25 Past
12-year reference product exclusivity ends (first biosimilar can be marketed) 2003-06-25 Past

Note: composition-of-matter and method-of-use patent expiries (separate from BPCIA exclusivity) may set the actual launch window. See NOVOLIN 70/30 on Drug Landscape for the full patent picture.

Other NOVO NORDISK INC biologics

Sources

Not legal advice. BPCIA exclusivity may interact with composition-of-matter patents and patent term extensions — see the full drug profile for the consolidated picture.

Track NOVOLIN 70/30 biosimilar entry

Daily alerts when BPCIA exclusivity, ref-product patents, or biosimilar applications change. Free 3 watches, Pro 50.